Premium
The N6‐methyladenosine mRNA methylase METTL14 promotes renal ischemic reperfusion injury via suppressing YAP1
Author(s) -
Xu Yao,
Yuan Xiao Dong,
Wu Jia Jin,
Chen Ruo Yang,
Xia Lei,
Zhang Ming,
Han Cong Hui,
Mou Shan
Publication year - 2020
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29258
Subject(s) - yap1 , n6 methyladenosine , gene knockdown , in vivo , kidney , messenger rna , cancer research , biology , acute kidney injury , pharmacology , microbiology and biotechnology , chemistry , medicine , methyltransferase , biochemistry , gene , endocrinology , transcription factor , genetics , methylation
Renal ischemia‐reperfusion injury (IRI) is one of the most common causes of acute kidney injury (AKI), which is closely related to high morbidity and mortality. However, the pathogenesis underlying renal IRI is complex and not fully defined. N6‐methyladenosine (m6A) was recently found to be an abundant modification in mammalian messenger RNAs. It is implicated in various biological processes, while the role of m6A in IRI is not illustrated. Here we show that the m6A‐methylated RNA level and its methyltransferase METTL14 are elevated in human AKI renal tissues and IRI HK‐2 cells. Moreover, METTL14 knockdown protects the kidney against IRI in vitro and in vivo. Mechanistically, we identified that YAP1 is a direct target of METTL14 in AKI progression. Inhibition of YAP1‐TEAD signaling by peptide 17 abrogates the protective effect of METTL14 against IRI in vitro and in vivo. Taken together, these results reveal that the N6‐methyladenosine mRNA methylase METTL14 promotes the renal IRI via suppressing YAP1. The discovery of the METTL14‐YAP1 pathway provides an important new perspective for understanding AKI and is conducive to revealing new therapeutic strategies and targets.